Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?

INTRODUCTION. Migraine is a highly prevalent neurological disease and the search for an effective treatment to improve the patient’s quality of life is essential. In 2018, anti-CGRP monoclonal antibodies were approved in Spain as a preventive treatment, and have proved to be effective in reducing th...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Moreno, Yolanda, Castro-Sánchez, M. Victoria, García-Trujillo, Lucía, Serrano-Castro, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Viguera Editores (Evidenze Group) 2022
Materias:
Original Breve
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280712/
https://www.ncbi.nlm.nih.gov/pubmed/35866533
http://dx.doi.org/10.33588/rn.7504.2021526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280712/
https://www.ncbi.nlm.nih.gov/pubmed/35866533
http://dx.doi.org/10.33588/rn.7504.2021526

Ejemplares similares